Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keystone Heart Ltd.

Division of Venus MedTech (HangZhou) Inc.
www.keystoneheart.com

Latest From Keystone Heart Ltd.

Start-Up Spotlight: Innovative Cardiovascular Solutions Hopes To Win Regulatory Nod For Embolic Protector For TAVR

Transcatheter aortic valve replacement (TAVR) is performed routinely using devices providing protection from stroke as standard of care. However, cerebral embolic protection devices currently available do not capture and remove emboli from all three vessels leading to the brain. The Emblok Embolic Protection System from Innovative Cardiovascular Solutions (ICS) has developed an embolic filter designed to protect all three cerebral vessels during TAVR and remove debris from the entire circulatory system.

Commercial Start-up Spotlight

Market Intel: Martin Leon's TAVR Technology Tour Of The Future

Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology. 

Surgical Procedures Cardiovascular

China's Venus Persists With Global TAVR Solutions Expansion

Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.

Commercial Deals

First TAVR Filter To Reach FDA Panel Will Get Questions On Missed Endpoint

Claret Medical’s Sentinel embolic protection device for transcatheter aortic valve replacement is set to go before US FDA’s Circulatory System Devices Panel on Feb. 23. Trials found the de novo device is safe, but the agency has some concerns that a primary efficacy endpoint was missed.

Cardiology Neurology
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Venus MedTech (HangZhou) Inc.
  • Senior Management
  • Chris Richardson, Pres. & CEO
    Amit Ashkenazi, COO & VP, R&D
    M. Pauliina Margolis, MD, PhD, VP, CMO
    Steve Sandweg, VP, Sales & Mkt. Dev.
  • Contact Info
  • Keystone Heart Ltd.
    Phone: (813) 530-8200
    3000 Bayport Dr., Ste. 980
    Tampa, FL 33607
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register